Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling

INTRODUCTION: Crizotinib is an oral multitargeted tyrosine kinase inhibitor (TKI) with activity against lung cancers driven by ALK-rearrangements, ROS1-rearrangements and MET-amplification. Comprehensive genomic profiling (CGP) based on clinical next generation sequencing (NGS) can detect crizotinib...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Lung Cancer
Huvudupphovsmän: Le, Xiuning, Freed, Jason A., VanderLaan, Paul A., Huberman, Mark S., Rangachari, Deepa, Jorge, Susan E., Lucena-Araujo, Antonio R., Kobayashi, Susumu S., Balasubramanian, Sohail, He, Jie, Chudnovksy, Yakov, Miller, Vincent A., Ali, Siraj M., Costa, Daniel B.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418215/
https://ncbi.nlm.nih.gov/pubmed/25922291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.002
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk